Evgen Pharma PLC (AIM:EVG), the clinical-stage drug development company, has announced the termination of its patent and know-how licence agreement with.
By Christian Moess Laursen Shares in Evgen Pharma dropped 13% on Wednesday after the company said it has ended a license agreement with JuvLife. At 0830 GMT,.
The following stocks are the leading risers and fallers on AIM in London on Wednesday.
AIM - WINNERS
Blancco Technology Group PLC, up 23% at 219.56 pence, 12-month range.